Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 4,502

Document Document Title
WO/2024/074126A1
Provided are a 4-methylsulfonylbenzamide compound having a structure represented by general formula (I) and having a sulfur-containing substituent at position 3, a stereoisomer thereof, an agriculturally acceptable salt thereof, a prepar...  
WO/2024/074648A1
The present invention relates to a method for precipitating the gadolinium complex of formula (I) from a solution comprising such gadolinium complex by means of mixing a first solution comprising the complex with a second solution, as we...  
WO/2024/067784A1
Provided are an amorphous form and 16 crystal forms of a compound represented by formula (I). The crystal forms are named in order from crystal form A to crystal form P. Also provided is a preparation method for the amorphous form and po...  
WO/2024/073155A1
A composition comprising a hydrogel includes a polymer of formula (1), at least one repeating unit of which comprises norbomene. Methods of treating wounds and methods of encapsulating drugs and/or cells using such hydrogels are also dis...  
WO/2024/052549A1
The present invention relates to a new class of compounds of general formula (I), to the metal chelates with a metal ion suitable for computed tomography thereof, to the Gd3+ chelate complexes thereof, to methods of preparing said compou...  
WO/2024/044552A1
Described herein are immunoconjugates comprising an: a) antigen binding region; b) an immunoglobulin heavy chain constant region; and c) a radioisotope chelating agent; wherein the molecular weight of said immunoconjugate is between 60 a...  
WO/2024/044549A1
Described herein are immunoconjugates comprising an: a) antigen binding region; b) an immunoglobulin heavy chain constant region; and c) a radioisotope chelating agent; wherein the molecular weight of said immunoconjugate is between 60 a...  
WO/2024/034686A1
The present invention provides a polymer contrast agent. The present invention relates to a copolymer in which a chelating agent molecule is bonded to a copolymer X constituted of structural units represented by formulae (A), (B) and (...  
WO/2024/035831A1
Tetrazolium-based compounds are described herein that are capable of undergoing reduction reactions under physiological conditions after crossing over the cell membrane. Reduction of the tetrazolium-based compounds results in ring-openin...  
WO/2024/036100A1
Disclosed are compounds of Formula (I): or a salt thereof, wherein: X, Y, Z, R1, R2, R3, and n are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (...  
WO/2024/028169A1
The present invention relates to novel thiophenolic compounds (I) which are useful in the treatment of proliferative and/or hyper-proliferative diseases. Preferably, the compounds of the present invention are endowed with inhibitory acti...  
WO/2024/030772A1
A compound has a structure according to formula IA or IB, or a salt or stereoisomer thereof: (IA) or (IB), where each R1 independently is an aryl or aliphatic group having an sp2‑hybridized or sp‑hybridized carbon at its attachment p...  
WO/2024/030651A1
The present disclosure provides a compound of Formula (I'), or a pharmaceutically acceptable salt thereof and its use in, e.g. treating a condition, disease, or disorder in which inhibiting GPX4 in a subject is of therapeutic benefit, sp...  
WO/2022/241470A9
Disclosed herein are methods of molecular magnetic resonance (MR) imaging and positron emission tomography using extracellular probes that target extracellular allysine aldehyde and act as a noninvasive biomarker of fibrogenesis with hig...  
WO/2024/023332A1
The invention relates to novel silicon-based fluoride acceptor groups (SiFA groups) of the following formulae (Ia, Ib, Ic) as well as to compounds suitable for use in radiopharmacy comprising such groups, wherein R1 and R2 are each a lin...  
WO/2024/020350A1
The present disclosure provides, in part, compounds of formula (I): wherein the variables are as defined herein, pharmaceutical compositions comprising the compounds, and methods of using the compounds to treat physiological disorders, s...  
WO/2024/017762A1
The present invention related to compounds of Formula (I): or an agronomically acceptable salt thereof, wherein R1, R2, R3, R4 and R5 are as described herein. The invention further relates to compositions comprising said compounds, to me...  
WO/2024/011414A1
Disclosed in the present invention is a reaction method for secondary amine and o-diiodobenzene, comprising: reacting secondary amine with o-diiodobenzene in the presence of an alkali metal hydride or a Grignard reagent to complete the r...  
WO/2024/013058A1
The present invention describes salts of SCO-101, crystals and amorphs thereof, as well as pharmaceutical compositions comprising the salts, methods for making them, and their use in treatment of cancer.  
WO/2023/237015A1
The present invention relates to the field of biological medicines. Disclosed are N-tetrazolyl aryl urea derivatives, a preparation method therefor, and the use thereof. The present invention has recently discovered the N-tetrazolyl aryl...  
WO/2023/239104A1
The present invention relates to a method for preparing dihydroxyammonium 5,5'-bistetrazole-1,1'-diolate. The method for preparing dihydroxyammonium 5,5'-bistetrazole-1,1'-diolate, according to one embodiment of the present invention, co...  
WO/2023/229859A1
During the production of Hexahydro-1, 3, 5-trinitro-l, 3, 5-triazine and Octahydro-1,3, 5, 7-tetranitro-l, 3,5, 7-tetrazocine via the Bachmann nitrolysis process, it is necessary to recover the entire mass of acetic acid and restore it t...  
WO/2023/220836A1
The present disclosure relates generally to new bifunctional linchpins that react selectively with cysteine residues to invoke cyclization while concurrently introducing a radiometal chelation ligand or silicon-based fluoride acceptor (S...  
WO/2023/222681A1
The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of PSMA-expressing cancers, especially prostate can...  
WO/2023/210510A1
Provided is a method for producing a radioactive metal complex comprising a complex forming step for causing a radioactive metal nuclide and a ligand compound represented by formula (1) to react with each other in a reaction solution con...  
WO/2023/211412A1
The present invention relates to a film coated tablet comprising intragranular composition comprising sacubitril sodium, valsartan disodium and an extragranular composition, wherein the tablet is obtained by dry granulation.  
WO/2023/209090A1
The specification relates to compounds of Formula (I): (I) and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in th...  
WO/2023/201374A1
The present disclosure is concerned with compounds and compositions for use in the prevention and treatment of cancer such as, for example, a primary or secondary tumor within a subject's brain, breast, kidney, pancreas, lung, colon, pro...  
WO/2023/201377A2
The present disclosure provides compounds and methods for "scission-enhanced" nuclear imaging and treatment ("SENIT"). In one example, the disclosure provides a conjugate where an affinity ligand (e.g., an antibody) is connected to a rad...  
WO/2023/196538A1
Substituted benzofuran, benzothiophene, and indole carboxamide compounds, conjugates, and pharmaceutical compositions for use as immunotherapeutics in the treatment of cancer, such as solid tumors, are disclosed herein. The disclosed com...  
WO/2023/190402A1
Provided is a method for producing a complex of a radioactive metal nuclear species and an antibody, the method comprising a step for reacting a radioactive metal nuclear species with an antibody modified with a coordination compound in ...  
WO/2023/180688A1
The following invention relates to methods of producing explosives from the nitration of TAT by flow synthesis. The invention relates to a method for the flow synthesis manufacture of HMX, (1,3,5,7-tetranitro-1,3,5,7-tetraazacyclooctane)...  
WO/2023/173618A1
The present invention provides a cyclic Gd(III) complex, which has a chemical structure as shown in formula I, wherein a ring structure of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid, namely DOTA, is used as a parent ring, l...  
WO/2023/170164A1
The present disclosure regards a method for providing labeled single isomeric chemical entity targeting vectors suitable for providing targeting vectors. The method applies specific combinations between a diene and a dienophile with comp...  
WO/2023/170174A1
The present disclosure regards a method for providing labeled single isomeric chemical entity targeting vectors suitable for providing targeting vectors. The method applies specific combinations between a diene and a dienophile with comp...  
WO/2023/172112A1
The present specification relates to a compound represented by chemical formula 1 and an organic light-emitting device comprising the compound.  
WO/2023/166511A1
One or more ionizable lipid(s) and lipid nanoparticles comprising same are provided. Pharmaceutical compositions comprising the lipid nanoparticles encapsulating an active agent are also provided.  
WO/2023/164775A1
A compound comprising a prostate specific membrane antigen (PSMA)-targeting moiety of the following formula (I) or of a salt or a solvate thereof. R1 is –R1aR1b– wherein R1a is absent, –CH2–, –O–, or –S–, and R1b is –CH...  
WO/2022/085570A9
The present invention pertains to a method that is for producing a radioactive zirconium labelled complex and that can achieve a high labelling rate in a reaction between a ligand compound and radioactive zirconium ions. The production m...  
WO/2023/158795A1
Provided are compounds of the Formula (I): or pharmaceutically acceptable salts thereof, which are useful for the inhibition of DHX9 and in the treatment of a variety of DHX9 mediated conditions or diseases, such as cancer.  
WO/2023/152711A1
The present invention relates to a process for the preparation of Cenobamate and intermediates thereof.  
WO/2023/148748A1
Disclosed herein is an improved, safe and novel method for the elimination of nitrosamine impurities during the preparation of sartan class of drugs containing tetrazole ring structure represented by general formula I, more particularly ...  
WO/2023/143612A1
Disclosed are a peptide urea derivative, a pharmaceutical composition containing the peptide urea derivative, and an application of the peptide urea derivative. The derivative is as represented by formula I, wherein R is a group containi...  
WO/2023/143354A1
The present invention relates to a tricyclic compound represented by formula (O), a pharmaceutical composition comprising the compound as an active ingredient, and an application thereof. The compound is an excellent TEAD inhibitor and c...  
WO/2023/122588A2
Compounds, e.g., radioimmunoconjugates, including a chelating moiety or a metal complex thereof, a linker, and an antibody or antigen-binding fragment thereof targeting both EGFR and cMET. Pharmaceutical compositions of such compounds an...  
WO/2023/121753A1
The present disclosure provides enynes, end-functionalized polymers, conjugates, methods of preparation, compositions, kits, and methods of use. The conjugates comprise at least (1) a peptide (e.g., an antibody), protein, nucleoprotein, ...  
WO/2023/116515A1
Disclosed in the present invention is a method for preparing high-purity losartan, which belongs to the fields of medicine and chemical engineering. The losartan is obtained by means of a multi-stage temperature reaction in the presence ...  
WO/2023/116514A1
The present invention belongs to the field of pharmaceutical and chemical engineering, and relates to a high-purity losartan potassium and a preparation method therefor. The present invention also relates to a high-purity losartan or a p...  
WO/2023/110867A1
The invention relates to a process for the preparation of the gadolinium dimeric contrast agent [p-[l-[bis[2-(hydroxy-KO)-3-[4,7,10-tris[(carboxy-KO)methyl] -l,4,7,10- tetraazacyclododec-l-yl-K/V1,K/V4,K/V7,K/V10]propyl]amino]-l -deoxy-D...  
WO/2023/110863A1
The present invention relates to a process for the manufacturing of a mixture comprising the intermediate 1-[bis[2-hydroxy-3-[4,7,10-tris[2-(1,1-dimethylethoxy)-2-oxo ethyl]-1,4,7,10-tetraazacyclododec-1-yl]propyl]amino]-1-deox y-D-gluci...  

Matches 1 - 50 out of 4,502